Carcinoma in situ of exocervix
ICD-10 D06.1 is a billable code used to indicate a diagnosis of carcinoma in situ of exocervix.
Carcinoma in situ of the exocervix refers to a localized form of cervical cancer where abnormal cells are found on the surface of the cervix but have not invaded deeper tissues. This condition is often detected through routine Pap smears, which identify atypical squamous cells. The exocervix is the part of the cervix that protrudes into the vagina, and carcinoma in situ indicates that the cancerous changes are confined to this area. While it is not invasive, it is considered a precursor to invasive cervical cancer if left untreated. Surveillance protocols typically involve regular Pap tests and HPV testing to monitor for any changes. The risk of progression to invasive cancer varies, with factors such as the presence of high-risk HPV types, the patient's age, and the adequacy of treatment influencing outcomes. Early detection and management are crucial to prevent progression.
Detailed pathology reports, treatment plans, and follow-up care documentation.
Routine Pap smear results indicating atypical cells, biopsy results confirming carcinoma in situ.
Ensure accurate documentation of HPV status and treatment options discussed with the patient.
Comprehensive treatment plans, including surgical and non-surgical interventions.
Management of patients with diagnosed carcinoma in situ and planning for potential invasive treatment.
Documenting the rationale for treatment decisions and any multidisciplinary discussions.
Used during routine screening for cervical cancer.
Document the reason for the test and any previous results.
Gynecologists should ensure that the patient's history of HPV is noted.
Performed when carcinoma in situ is diagnosed.
Document the extent of the lesion and the surgical approach.
Oncologists should document the rationale for excision versus observation.
Carcinoma in situ of the exocervix is a critical precursor to invasive cervical cancer. Early detection and treatment can prevent progression, making regular screening essential.
Patients should follow a surveillance protocol that typically includes Pap tests and HPV testing every 6 to 12 months, depending on individual risk factors and treatment history.
